





















![]()
Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease May 1, 2026 8:00 AM EDT
Company Participants
Mark Jacobson - Chief Operating Officer
Herriot Tabuteau - Founder, Chairman, CEO & President
Ari Maizel - Chief Commercial Officer
Nick Pizzie - Chief Financial Officer
Conference Call Participants
Jeffrey Cummings
Leonid Timashev - RBC Capital Markets, Research Division
Ami Fadia - Needham & Company, LLC, Research Division
John Cox - Jefferies LLC, Research Division
Ashwani Verma - UBS Investment Bank, Research Division
David Amsellem - Piper Sandler & Co., Research Division
Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division
Benjamin Burnett - Wells Fargo Securities, LLC, Research Division
Jason Gerberry - BofA Securities, Research Division
Joseph Thome - TD Cowen, Research Division
David Hoang - Deutsche Bank AG, Research Division
Guofang Li - Wolfe Research, LLC
Sean Laaman - Morgan Stanley, Research Division
Graig Suvannavejh - Mizuho Securities USA LLC, Research Division
John Boyle - William Blair & Company L.L.C., Research Division
Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division
Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division
Eddie Hickman - Guggenheim Securities, LLC, Research Division
Presentation
Operator
Good morning, and welcome to the Axsome Therapeutics conference call. [Operator Instructions] As a reminder, today's conference call is being recorded.
I would now like to turn the conference over to your host, Mark Jacobson, Chief Operating Officer of Axsome Therapeutics. Please go ahead.
Mark Jacobson
Chief Operating Officer
Thank you, operator. Good morning. Thank you all for joining us on today's conference call to discuss the approval of Auvelity for the treatment of agitation associated with dementia due to Alzheimer's disease.
During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our agents, our clinical and non-clinical plans, our plans to present or report additional data, the anticipated
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。